August 2nd 2012
Dr. Alan Sandler from the Oregon Health & Science University Discusses Immunotherapies for Lung Cancer
July 26th 2012
It is difficult to overstate the excitement surrounding the development of two new effective therapeutic strategies in the management of metastatic melanoma.
July 25th 2012
Research presented at ASCO 2012 examined the expanded use of sipuleucel-T, as well as methods to determine which patients might benefit the most from the therapy.
July 18th 2012
Preliminary data suggest a promising role for sipuleucel-T as a treatment for African-American men with metastatic castration-resistant prostate cancer (mCRPC).
July 10th 2012
Dr. Lawrence Fong from University of California, San Francisco, Discusses Immune Response to Sipuleucel-T
June 27th 2012
Immunotherapy is maintaining its momentum in clinical development programs, with explorations under way in many tumor types, including breast and lung cancers previously considered poor candidates for such modalities.
June 22nd 2012
Dr. Suzanne Topalian, from the Johns Hopkins University School of Medicine, on the PD-1 Targeted Immunotherapy BMS-936558.
In the past few years the pace of discovery of effective immunotherapies has accelerated as a consequence of better chemistry and understanding of immune biology.
June 21st 2012
Kathleen Madden, from NYU Langone Medical Center, on the Importance Educating Patients About Ipilimumab's Side Effects.
June 18th 2012
Dr. Charles Ryan, from UCSF Helen Diller Family Comprehensive Cancer Center, Discusses Sequencing Castration-Resistant Prostate Cancer Therapies.
June 14th 2012
While many approaches to using immunotherapy for the treatment of prostate cancer are under study, four strategies currently in later-stage clinical development have emerged as the most promising.
June 7th 2012
Dr. Julie Brahmer, from the Sidney Kimmel Comprehensive Cancer Center, on the PD-1 Immunotherapy BMS-93655 Clinical Trial
June 2nd 2012
An immunotherapy agent that targets the PD-1 pathway demonstrated response rates as high as 28% in an early-phase study involving patients with different tumor types.
May 31st 2012
Dr. Raoul Concepcion, from Urology Associates, PC, Nashville, TN, Discusses New Prostate Cancer Therapies.
May 24th 2012
Krista Rubin, from Massachusetts General Hospital Cancer Center, on Understanding Ipilimumab's Toxicities.
May 22nd 2012
Ipilimumab generates antitumor activity in some patients with advanced melanoma whose disease has metastasized to the brain without resulting in unexpected toxicities.
May 21st 2012
Dr. Leonard Gomella, from the Jefferson Kimmel Cancer Center, on the Provenge IMPACT Trial Survival Benefit
May 11th 2012
The neoadjuvant administration of sipuleucel-T may stimulate an immune response in patients with localized prostate cancer without adversely affecting their surgeries.
May 9th 2012
After a long fight with melanoma, the Roman Catholic parish priest Father Arthur Humphrey was able to receive the immunotherapeutic agent Yervoy, which greatly improved his prognosis.
May 6th 2012
Krista Rubin, MS, RN, FNP-BC, from Massachusetts General Hospital Cancer Center, on Managing Ipilimumab-related Dermatitis.
